{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:55:08Z","timestamp":1792086908082,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41375-019-0611-9","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T13:12:42Z","timestamp":1571663562000},"page":"947-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma"],"prefix":"10.1038","volume":"34","author":[{"given":"Clare M.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-9066","authenticated-orcid":false,"given":"Ramkrishna","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald Z.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Eischen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"611_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin."},{"key":"611_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Radford JA. Brentuximab vedotin for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:1560\u20131.","journal-title":"N Engl J Med."},{"key":"611_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol."},{"key":"611_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68:116\u201332.","journal-title":"CA Cancer J Clin."},{"key":"611_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","volume":"90","author":"SM Ansell","year":"2015","unstructured":"Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90:1574\u201383.","journal-title":"Mayo Clin Proc."},{"key":"611_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56\u201364.","journal-title":"Cell Death Differ."},{"key":"611_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","volume":"8","author":"CM Adams","year":"2018","unstructured":"Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 2018;8:636.","journal-title":"Front Oncol."},{"key":"611_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","volume":"130","author":"MS Davids","year":"2017","unstructured":"Davids MS. Targeting BCL-2 in B-cell lymphomas. Blood. 2017;130:1081\u20138.","journal-title":"Blood."},{"key":"611_CR9","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-17-1144","volume":"23","author":"CM Adams","year":"2017","unstructured":"Adams CM, Mitra R, Gong JZ, Eischen CM. Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. Clin Cancer Res. 2017;23:7119\u201329.","journal-title":"Clin Cancer Res."},{"key":"611_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood.V85.10.2671.bloodjournal85102671","volume":"85","author":"D Schlaifer","year":"1995","unstructured":"Schlaifer D, March M, Krajewski S, Laurent G, Pris J, Delsol G, et al. High expression of the bcl-x gene in Reed\u2013Sternberg cells of Hodgkin\u2019s disease. Blood. 1995;85:2671\u20134.","journal-title":"Blood."},{"key":"611_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1046\/j.1365-2141.1996.423958.x","volume":"92","author":"L Xerri","year":"1996","unstructured":"Xerri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol. 1996;92:900\u20136.","journal-title":"Br J Haematol."},{"key":"611_CR12","first-page":"2114","volume":"9","author":"M Herling","year":"2003","unstructured":"Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed\u2013Sternberg cells of classical Hodgkin\u2019s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003;9:2114\u201320.","journal-title":"Clin Cancer Res."},{"key":"611_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1349-7006.2007.00491.x","volume":"98","author":"T Kawasaki","year":"2007","unstructured":"Kawasaki T, Yokoi S, Tsuda H, Izumi H, Kozaki K, Aida S, et al. BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. Cancer Sci. 2007;98:1070\u20137.","journal-title":"Cancer Sci."},{"key":"611_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1073\/pnas.1524668113","volume":"113","author":"W Ju","year":"2016","unstructured":"Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin\u2019s lymphoma. Proc Natl Acad Sci USA. 2016;113:1624\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"611_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1080\/10428190902943069","volume":"50","author":"A Jayanthan","year":"2009","unstructured":"Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009;50:1174\u201382.","journal-title":"Leuk Lymphoma."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0611-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:24Z","timestamp":1684618704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0611-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0611-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}